Brief: Reata Pharmaceuticals Announces That The FDA Does Not Plan To Hold An Advisory Committee Meeting To Discuss The NDA For Omaveloxolone For Friedreich’S Ataxia
13/10/2022 21:38
Oct 13 (Reuters) - Reata Pharmaceuticals Inc RETA.O :
* REATA PHARMACEUTICALS ANNOUNCES THAT THE FDA DOES NOT PLAN
TO
HOLD AN ADVISORY COMMITTEE MEETING TO DISCUSS THE NDA FOR
OMAVELOXOLONE FOR FRIEDREICH’S ATAXIA
Source text for Eikon: ID:nBw9mxG1Ha
Further company coverage: RETA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Reata Pharmaceuticals
See all newsReata Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Reata Pharmaceuticals Inc expected to post a loss of $2.88 a share - Earnings Preview
Brief: Biogen Inc Says If Deal Terminated Under Certain Conditions, Reata Will Be Required To Pay Biogen Termination Fee Equal To $264 Mln
U.S. STOCKS ON THE MOVE-US regional banks, Enphase, Centene
Biogen’s $7 bln deal goes smaller and safer